Abstract
Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.
Original language | English (US) |
---|---|
Pages (from-to) | E00484 |
Journal | Clinical and translational gastroenterology |
Volume | 13 |
Issue number | 4 |
DOIs | |
State | Published - Apr 28 2022 |
Funding
Potential competing interests: B.S.B. reports consulting fees from Celgene and Takeda and research grants from Prometheus Biosciences and Gilead. A.E.C. reports consulting fees and speaking fees from AbbVie, Bristol Myers Squibb, Janssen, and Takeda. A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. ACKNOWLEDGMENTS Financial support: This work was supported by NIH K23 DK123406 (B.S.B.), NIH P30 DK120515 (B.S.B.), NIH T15LM011271 (N.H.N.), NIH 75N9301900065 (D.W., A.S.), NIH U19AI142742 (Shane Crotty), and NIH K08 AI135078 (J.M.D.).
ASJC Scopus subject areas
- Gastroenterology